Investment Funds
Venture Investment Funds Supporting Business Commercialization
Funding is essential for business growth and expansion. KSP has established venture investment funds to provide direct financing to promising companies.
KSP, Inc. became a Qualified Institutional Investor (QII) on January 31, 2020. KSP funds invest primarily in high-growth deep-tech ventures at the early and middle stages of development. To date, KSP has managed eight investment funds with combined capital contributions of ¥8.354 billion, and 20 portfolio companies have gone public.
KSP’s venture investment funds have earned a reputation for prudent investment, helping to strengthen the credibility of the companies they support.
If you need funding for research and development to commercialize your business, please contact us even if you have no prior experience raising equity capital.
Overview of KSP Funds
As of April 30, 2026
| Date Formed |
Fund Name | Total Capital Contributions |
Companies Invested In |
Listed Companies |
Investment Performance / Status |
|---|---|---|---|---|---|
| Sep. 2022 | NextG Investment Limited Partnership | ¥2.10 billion | 18 | — | Operating |
| Dec. 2021 | OSTC Investment Limited Partnership (Okinawa Innovation Creation Fund) |
¥444 million | 6 | — | Operating |
| Jan. 2020 | KSP No. 6 Investment Limited Partnership | ¥400 million | 13 | — | Operating |
| Oct. 2017 | KSP No. 5 Investment Limited Partnership | ¥400 million | 13 | 3 | Operating |
| Jun. 2014 | KSP No. 4 Investment Limited Partnership | ¥1.30 billion | 28 (investment period ended) |
9 | Operating |
| Jul. 2006 | KSP No. 3 Investment Limited Partnership | ¥2.40 billion | 54 (fund closed) | 6 | 80.0% |
| Mar. 2004 | KSP No. 2 Investment Limited Partnership | ¥610 million | 26 (fund closed) | 1 | 196.7% |
| Jan. 1997 | KSP No. 1 Investment Partnership (Civil Code partnership) |
¥700 million | 25 (fund closed) | 4 | 442.9% |
Public Listing Track Record
| Listing Date | Market at Listing | Company | Business Activities |
|---|---|---|---|
| Mar. 2026 | TSE Growth Market | J-Pharma Co., Ltd. | Development of pharmaceuticals for novel cancer treatments |
| Mar. 2024 | TSE Growth Market | STG Co., Ltd. | Development and manufacture of magnesium and aluminum die-cast products |
| Dec. 2022 | TSE Growth Market | Cyfuse Biomedical K.K. | Development, manufacture, and sale of regenerative medicine products |
| Nov. 2022 | TSE Growth Market | TMS Co., Ltd. | Research and development of pharmaceuticals, quasi-drugs, pharmaceutical ingredients, medical devices, and medical consumables |
| Sep. 2021 | TSE Mothers | Renascience Inc. | Development and sale of pharmaceuticals, medical devices, and AI-based solutions |
| Sep. 2021 | TSE Mothers | Mobilus Corporation | Development and sale of conversational application software and contract software development |
| Dec. 2020 | TSE Mothers | Kringle Pharma, Inc. | Development of recombinant human HGF therapeutics for acute spinal cord injury and amyotrophic lateral sclerosis (ALS) |
| Aug. 2019 | TSE Mothers | StemRIM Inc. | Development of regeneration-inducing pharmaceuticals (peptide-based medicines) |
| Jun. 2019 | TOKYO PRO Market | STG Co., Ltd. | Integrated production of magnesium and aluminum die-cast products |
| Mar. 2019 | TSE Mothers | MINKABU THE INFONOID, Inc. | Development and operation of AI-powered information media |
| Nov. 2018 | TOKYO PRO Market | Tsukuba Seiko Co., Ltd. | Development and manufacture of electrostatic adsorption systems |
| Oct. 2015 | TSE Mothers | GreenPeptide Co., Ltd. (now BrightPath Biotherapeutics Co., Ltd.) | Research and development of cancer vaccines |
| Aug. 2015 | TSE Mothers | PCI Holdings, Inc. | Software development and development and maintenance of proprietary solutions |
| Jun. 2013 | JASDAQ | REPROCELL Inc. | Sale of research reagents for ES and iPS cells |
| Dec. 2011 | TSE Mothers | Chiome Bioscience Inc. | Research and development of antibody therapeutics and related support services |
| Dec. 2011 | TSE Mothers | W-SCOPE Corporation | Manufacture and sale of separator films for rechargeable batteries |
| Oct. 2011 | JASDAQ | SymBio Pharmaceuticals Limited | Development and commercialization of pharmaceuticals for cancer, hematologic disorders, and autoimmune diseases |
| Mar. 2006 | JASDAQ | MEDIA GLOBAL LINKS CO., LTD. (now MEDIA LINKS CO., LTD.) | Development, manufacture, and sale of telecommunications and broadcasting equipment |
| Mar. 2005 | Nagoya Stock Exchange Centrex | Effector Cell Institute Inc. | Drug discovery for cancer and allergies, and development and sale of cell chemotaxis measurement devices |
| Aug. 2004 | TSE Mothers | SIOS Technology Inc. (now SIOS Corporation) | Development of Java- and Linux-related products and implementation of enterprise information systems |
| Sep. 2003 | JASDAQ | Techno Medica Co., Ltd. | Research, development, manufacture, sale, import, and export of clinical testing analyzers and other medical devices |
Investment Criteria
- Qualities and capabilities of the management team
- Novelty and innovativeness of the technology and business model
- Market size, market potential, and competitive landscape
- Soundness and feasibility of the business plan
- Appropriateness of the capital structure and other financing plans
Investment Committee Members
- President, Managing Director, or other full-time directors of KSP, Inc.
- Technical experts from the Kanagawa Institute of Industrial Science and Technology (KISTEC)
- Advisory Board members, including CEOs of venture companies that have completed an IPO